Metazym
Experimental recombinant enzyme
From Wikipedia, the free encyclopedia
Metazym is an experimental recombinant enzyme that was studied in patients with late infantile metachromatic leukodystrophy,[1] but found to be ineffective under the conditions of that trial. A subsequent clinical trial is ongoing.[2] The drug became a source of controversy when a family attempted to purchase the drug for their child before it was approved.[3] Jonckheere, Kingma, Eyskens, Bordon, & Jansen (2023) highlight the shift towards the need for newborn screening for metachromatic leukodystrophy as it allows for improved early detection and timely treatment as well.[4]
